Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of sonrotoclax (BGB-11417) alone and in dexamethasone-based combinations for relapsed/refractory multiple myeloma with t(11;14)
2023-507751-30-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of sonrotoclax in multiple myeloma (MM) (6 arms), sponsored by BeOne Medicines. Primary endpoints: Safety and tolerability in Part 1 dose escalation, Safety and tolerability in Part 2 cohort expansion and 3 more. Planned start May 2024; status: authorised.
02
Drugs
sonrotoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-507751-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507751-30-00.